Capricor Therapeutics(NASDAQ) CAPR

Capricor Therapeutics helps doctors treat patients with a rare muscle disease. The company makes cell-based medicines to slow down heart and muscle damage. These treatments aim to help young people live longer lives.

What's in the Medicine Cabinet?

• Deramiocel: Cell therapy made from donor heart cells to treat heart and muscle complications for patients with Duchenne muscular dystrophy (DMD); no product revenue reported as of June 30, 2026.
• StealthX Vaccines: Internal platform that uses exosomes to carry proteins that help the body fight infectious diseases.
• StealthX Therapeutics: Technology designed to deliver protein and small molecule treatments directly to targeted cells in the body.

Building a Pathway to Patients

• Submitted a Biologics License Application (BLA) for Deramiocel to the Food and Drug Administration (FDA) in late 2024.
• Partnered with Nippon Shinyaku for the exclusive distribution of its lead product in the United States on Jan. 24, 2022.
• Expanded the partnership with Nippon Shinyaku to include exclusive distribution rights in Japan on Feb. 10, 2023.
• Entered the Project NextGen initiative to develop durable vaccines for COVID-19 with the National Institutes of Health.
• Resubmitted clinical data to the FDA to address a previous response letter with a target action date of Aug. 22, 2026.

Science Behind the Cells

Capricor uses exosomes to deliver therapeutic cargo to cells with low risk of being recognized by the immune system. The company has conducted clinical trials involving over 200 patients to assess the safety and performance of its cardiac cell therapies.

Key Financial Figures

• Market capitalization reached $1.4 billion in Q2 2026, up 207.3% year over year.
• Total cash, cash equivalents, and marketable securities were approximately $237.9 million as of June 30, 2026.
• Research and development expenses were $56.2 million for the six-month period ended June 30, 2026, up 37% year over year.
• General and administrative expenses reached $23.5 million for the six-month period ended June 30, 2026, up 100% year over year.

Bottom Line

Capricor is moving from laboratory research toward the potential commercial sale of its first cell therapy for rare diseases. The company is currently managing high development costs while waiting for final regulatory decisions in the United States and international markets.